Moreover, the activation of numerous regulatory pathways within AML LSCs, including dysregulation of the OXPHOS pathway, perturbed cholesterol homeostasis, and aberrant MYC activity, has been associated with chemoresistance, thereby presenting formidable challenges in AML treatment. The gene discussed is MYC; the disease is acute myeloid leukemia.